Navigation Links
Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
Date:6/15/2008

SEATTLE, June 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced the Company has repaid the remaining balance, including accrued interest, of its 2008 Convertible Notes which reached maturity on June 15, 2008 through a cash payment of approximately $11.0 million. The Company currently has no debt maturing before Q3 2010.

"Retiring this last piece of current debt provides the Company more than 24 months to deliver our sales and product milestones before any additional convertible notes become due," said James A. Bianco, M.D., President and CEO of CTI.

The cash payment for the retirement of the 2008 Convertible Notes is the most recent step taken by the Company to improve its financial position including previously restructuring and retiring other convertible debt and preferred securities as well as recent financings that increased its cash position and institutional investor ownership.

This press-release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the Company continues to have negative cash flow and a significant amount of debt outstanding, redeemable preferred stock outstanding and will need to raise additional capital to fund its operations; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Lindsey Jesch

T : 206.272.4347

F : 206.272.4434

E: media@ctiseattle.com

'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
2. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
3. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
4. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
7. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
8. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
9. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
10. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
11. Cell Therapeutics, Inc. Announces Filing of Form 10-K
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...SIK Surgeons launched its revolutionary Trusted LA....TrustedLASIKSurgeons.com in order to provide a r...ion. What sets the Trusted LASIK Surgeons director...t only those who are among the best in LASIK eye s...are listed. Refractive eye surgeons, such as Dr. ...
(Date:12/4/2008)...all/ -- ExonHit Therapeutics S.A.,(Alternext: ALE...leased to,announce today that it has been honoure...roperty) during the last edition of its "Trophee d...nce its inception, ExonHit consistently made effor...tellectual property and in particular from its,in...
(Date:12/3/2008)...first- and secondhand smoke, an estimated ten perc...posure of a developing baby to harmful cigarette b...ted 420,000 newborns each year and poses a signifi...dy of its kind, a team of researchers has complete...blood to better understand the fetal health risks ...
(Date:12/3/2008)...Agreement Executed to Support ConjuChem,s, R...RD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - Conju...Biopharma UK Ltd., a subsidiary of Novozymes A/S (...ntered into a long-term Manufacturing and Supply A...vely supply its recombinant human albumin, Recombu...
Breaking Biology Technology:Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 2Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 3Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 4Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 5Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 6Houston LASIK Eye Surgery Expert and Pioneer Jack Holladay, M.D. Joins Influential Group of Eye Surgeons Listed at Trusted LASIK Surgeons 7ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 2ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 3Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 2ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 3
... , , , , , , This applic...ty of,absolute protein quantitation of the Agile...ein 200 Plus assay to the batch-based methods,Lo...rophoresis (SDSPAGE).,The results showed that th...iable absolute quantitation data comparable to the...
...expert software , Powerful software for th...he Agilent 2100 bioanalyzer , , , , ...is a,unique, on-chip, electrophoresis and,flow...nd cells., , , Agilents single software ...software for the 2100 bioanalyzer ,incorporating...
... , , , , , , A fast and ...n,expression in samples of low cell numbers ,...he major problems,that many researchers working,...availability, quantity,and lifespan. Using the A...LabChip kit the transfection,efficiency of prima...
... , , , , , , This Applic...zer and,the Cell Fluorescence LabChip kit can be...n of mammalian cells using green fluorescent prote... CHO-K1 cells with,expression vectors encoding G...of transfection conditions for both plasmids were ...
Other Biology Technology:Comparison of different protein,quantitation methods 2Comparison of different protein,quantitation methods 3Comparison of different protein,quantitation methods 4Comparison of different protein,quantitation methods 5Comparison of different protein,quantitation methods 6Comparison of different protein,quantitation methods 7Comparison of different protein,quantitation methods 8Comparison of different protein,quantitation methods 92100 expert software , Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer 2Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 2Flow cytometric analysis of human,primary cells using the Agilent 2100,bioanalyzer and on-chip staining 3Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 2Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 3Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 4Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 5Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 6Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 7
(Date:12/3/2008)...FORE"...Though they may not help improve a person,...ay golfers think about the local country club in t...ouri study. , "There are more than 17,000 golf c...percent of that land is not used for playing," sai... the MU College of Arts and Science. "These manage...
(Date:12/3/2008)...EMBER 1, 2008 -- As the United States continues to...ds energy independence, cellulosic-based ethanol h...technologies. Corn stover remains the most popular...rbon (SOC) associated with the removal of corn fod...ltural and environmental concern. , In the Nov...
(Date:12/3/2008)...roblem of children failing to take their medicatio...be tackled as part of a new university research pr...cialists at The University of Nottingham and The U...s of school children with asthma, diabetes, congen... barriers that prevent them from taking medicines ...
(Date:12/3/2008)...ion team of investigators led by researchers at th...thern California (USC) has received $19 million in...alth (NIMH) for a groundbreaking effort to collect...nts in order to study the genetic risks for schizo...for Genomic Psychiatry and Massachusetts General H...
Breaking Biology News(10 mins):Golf course: Playing fields, wildlife sanctuaries or both 2Managing carbon loss 2A spoonful of sugar? 2A spoonful of sugar? 3USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 2USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 3Catalyst Pharmaceutical Partners to Present at the Rodman 26 Renshaw 10th Annual Global Investment Conference 8813 1Catalyst Pharmaceutical Partners to Present at the Rodman 26 Renshaw 10th Annual Global Investment Conference 8813 2MiddleBrook Pharmaceuticals Retains National Account Firm VCG 26 Associates 28516 1MiddleBrook Pharmaceuticals Retains National Account Firm VCG 26 Associates 28516 2MiddleBrook Pharmaceuticals Retains National Account Firm VCG 26 Associates 28516 3Survey Reveals Consumer Interest in New Media Formats for Health Information From Hospitals 28515 1Survey Reveals Consumer Interest in New Media Formats for Health Information From Hospitals 28515 2Survey Reveals Consumer Interest in New Media Formats for Health Information From Hospitals 28515 3Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008 8808 1Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008 8808 2Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008 8808 3Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008 8808 4
...erous studies has helped scientists examine specif...ence, according to a study in the October 4 issue ... , The Breast Cancer Association Consortium brou...ing breast cancer research. Numerous studies by th...of single nucleotide polymorphisms, single variati...
...mory T cells vanish within weeks after a person is...Aaron Diamond AIDS Research Center and the Bernard...en-access journal PLoS Medicine, researchers repor...igestive tract, tend not to return to normal even ...s, HIV infection has been shown to deplete the bod...
...intravenously could be used as an agent to protect...zing radiation in the event of large-scale exposur...o an animal study presented today by University of... of the American Society for Therapeutic Radiology... radiation can be extremely damaging to cells, tis...
...rus (RYMV) was first identified in 1966 in Kenya. ...es where rice is grown. The disease is characteriz...eath on the leaves. The fertility and development ...ield losses at harvest. , Transmission of RYMV oc...d contact between plants. Prevention measures, lik...
Other Biology News:Early HIV treatment fails to restore memory T cells 2Intravenous gene therapy protects normal tissue of mice during whole-body radiation 2Discovery of the first resistance gene to rice yellow mottle virus 2Discovery of the first resistance gene to rice yellow mottle virus 3
GOAT ANTI HUMAN FACTOR 8RELATED ANTIGEN
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds.
EoProbe Eosinophil Staining Kit, 1 Kit
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other
Biology Products: